Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Therapy-related Toxicity Clear all
Completed Phase 3 Interventional Results available

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

NCT00358501
View directory record Official record
Conditions
Severe Hepatic Veno-Occlusive Disease
Interventions
Defibrotide
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
22
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Jul 23, 2026, 11:27 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer

NCT00028964
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
Chinese herbs, cyclophosphamide, doxorubicin hydrochloride, adjuvant therapy
Dietary Supplement · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2011 · Synced Jul 23, 2026, 11:27 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NCT00016276
View directory record Official record
Conditions
Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jul 23, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional

Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

NCT06045793
View directory record Official record
Conditions
Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse, Cocaine Adverse Reaction
Interventions
TNX-1300 (Injection), Placebo (Injection)
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Lexington, Kentucky • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jul 23, 2026, 11:27 AM EDT
Recruiting Phase 2 Interventional

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

NCT05559164
View directory record Official record
Conditions
Cardiac Toxicity, Early-stage Breast Cancer
Interventions
Lipitor 40mg Tablet
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 23, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

NCT00941070
View directory record Official record
Conditions
Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
Interventions
triapine, cisplatin, external beam radiation therapy, quality-of-life assessment, questionnaire administration, fludeoxyglucose F 18, positron emission tomography, computed tomography
Drug · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jul 23, 2026, 11:27 AM EDT
Recruiting Phase 2 Interventional

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

NCT03480971
View directory record Official record
Conditions
Mucositis, Nephrotoxicity, Ototoxicity
Interventions
Tempol, Placebo Solution
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
La Jolla, California • Merced, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 23, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00004176
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions
amifostine trihydrate, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
4
States / cities
Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Jul 23, 2026, 11:27 AM EDT
Active, not recruiting Phase 2 Interventional

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

NCT04469075
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Skin Toxicity
Interventions
Clindamycin Phosphate, Triamcinolone Acetonide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Evanston, Illinois • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 23, 2026, 11:27 AM EDT
Withdrawn Phase 2 Interventional

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

NCT00003407
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions
amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Chicago, Illinois • Kankakee, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 23, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes

NCT00004567
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:27 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

NCT02319616
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Clobetasol 0.05% ointment, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
7 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Jul 23, 2026, 11:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

NCT02037347
View directory record Official record
Conditions
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Interventions
Palifermin
Drug
Lead sponsor
Brett King
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Bridgeport, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Jul 23, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

NCT00074165
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
Interventions
Rituxan, Cyclophosphamide, Etoposide, Etoposide phosphate, Carboplatin, Sodium thiosulfate, Neupogen, Neulasta, Cytarabine
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Months to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Jul 23, 2026, 11:27 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

NCT00005796
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions
filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation
Procedure · Biological · Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 23, 2026, 11:27 AM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

NCT00004036
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, carboplatin, cyclophosphamide
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Jul 23, 2026, 11:27 AM EDT
Completed No phase listed Observational

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

NCT01416688
View directory record Official record
Conditions
Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Interventions
assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
113
States / cities
Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 23, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

NCT00055718
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
silymarin
Dietary Supplement
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
2 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
7
States / cities
Miami, Florida • Mineola, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 23, 2026, 11:27 AM EDT
Terminated Not applicable Interventional

Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer

NCT02370264
View directory record Official record
Conditions
Musculoskeletal Complication, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Therapy-Related Toxicity
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Medical Chart Review
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jul 23, 2026, 11:27 AM EDT
Completed No phase listed Observational Results available

Optimizing Vancomycin Therapy in Children

NCT05691309
View directory record Official record
Conditions
Sepsis, Critical Illness, Infections, Drug Toxicity
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jul 23, 2026, 11:27 AM EDT
Completed Not applicable Interventional

A Standardized Nursing Intervention Protocol for HCT Patients

NCT00951626
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Psychosocial Effects of Cancer and Its Treatment, Therapy-related Toxicity
Interventions
exercise intervention, telephone-based intervention, dietary intervention, educational intervention, questionnaire administration, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, assessment of therapy complications, peripheral blood stem cell transplantation, psychosocial assessment and care, quality-of-life assessment, standard follow-up care
Behavioral · Dietary Supplement · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 23, 2026, 11:27 AM EDT
Completed No phase listed Observational Results available

Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors

NCT01015326
View directory record Official record
Conditions
Skin Toxicities
Interventions
Questionnaire
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Jul 23, 2026, 11:27 AM EDT
Not listed Phase 2 Interventional

Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

NCT00003583
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions
amifostine trihydrate, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jul 23, 2026, 11:27 AM EDT
Completed Phase 3 Interventional

NATIENS: Optimal Management and Mechanisms of SJS/TEN

NCT02987257
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 11:27 AM EDT